RSV vaccines for older adults are now available at Walgreens.

Walgreens is now offering the respiratory syncytial virus vaccine for older adults nationwide, as announced by the pharmacy chain on Tuesday.

Individuals aged 60 and above can easily schedule an appointment this week through Walgreens’ user-friendly app, convenient website, by phone, or by visiting their local pharmacy.

This marks the inaugural RSV season in which older adults have the choice to receive the vaccine. Last spring, the Food and Drug Administration granted approval to Pfizer and GSK for their first RSV vaccines.

Walgreens is providing both Pfizer’s and GSK’s shots, which are administered as a single dose.

RSV typically spreads more extensively during the autumn season. The virus claims the lives of 6,000 to 10,000 older adults and leads to the hospitalization of 60,000 to 160,000 individuals annually, as reported by the Centers for Disease Control and Prevention.

The CDC recommends eligible adults consult their healthcare provider regarding the necessity of receiving the vaccine.

The RSV vaccines are currently accessible in most states, with additional appointments being added gradually over the next two weeks as more pharmacies receive the vaccine shipments, according to Walgreens.

At present, Walgreens pharmacies are not authorized to administer RSV vaccines in DC, Maryland, Massachusetts, and New York. However, the company anticipates the availability of the shots in these locations in due course, as stated by a spokesperson.

A doctor’s prescription is required for individuals residing in Georgia, Iowa, Indiana, Kentucky, Missouri, Oregon, Puerto Rico, South Carolina, and Utah in order to receive the shots, the spokesperson added.

CVS has been contacted by CNBC to inquire whether they will also have RSV vaccines available prior to the fall season.

Pfizer began direct shipping of its RSV vaccine to customers last month and has ample supply to meet demand, states a company spokesperson. CNBC has reached out to GSK for comment.

Pfizer’s shot displayed an efficacy of 85.7% in preventing more severe lower respiratory tract disease during the patient’s first RSV season after vaccination. The efficacy slightly declined to 78.6% after approximately 18 months.

GSK’s shot showcased an efficacy of 94% against severe RSV disease in the patient’s season immediately following vaccination, which reduced to about 78.8% after two RSV seasons.

— This story includes contributions from CNBC’S Annika Kim Constantino.